GLP-1 agonists
Coverage of GLP-1 agonists in the Nexus archive.
- GLP-1 drugs could become personalized for individuals, study says
A study suggests GLP-1 drugs could be personalized for individuals, with higher-dosage GLP-1 agonists showing greater cardiometabolic improvements.
- Doctors reveal hidden danger for some Ozempic, Wegovy users with brain disorders
Neurologists warn that GLP-1 agonists like Ozempic and Wegovy, which promote rapid weight loss, may worsen neurodegenerative conditions such as ALS by accelerating physical decline. A case report shows an ALS patient’s condition deteriorated after using semaglutide, stabilizing only after discontinuation.
- Medicare Is Now Covering Some GLP-1s for Weight-Loss for $50. Here's What to Know
Medicare is now covering some GLP-1 agonists for weight loss at a reduced cost of $50 for eligible older Americans. The federal government began offering these medications to certain Medicare beneficiaries this week, making previously expensive treatments more affordable.
- Guts may hold the key to happiness
New research on mouse gut microbiomes suggests GLP-1 drugs like Ozempic may reduce depression and anxiety symptoms by altering gut bacteria, specifically increasing Lactobacillus delbrueckii, which produces stress-calming compounds. The study highlights a brain-gut connection linking these diabetes/weight-loss drugs to mood regulation.